Glucokinase (Hexokinase-D or Hexokinase Type IV or EC 2.7.1.2) - Pipeline Review, H1 2016

  • ID: 3788906
  • Drug Pipelines
  • 56 pages
  • Global Markets Direct
1 of 6

FEATURED COMPANIES

  • Advinus Therapeutics Ltd
  • Amgen Inc.
  • LG Life Science LTD.
  • Novartis AG
  • Poxel SA
  • Teijin Pharma Limited
  • MORE
Glucokinase (Hexokinase-D or Hexokinase Type IV or EC 2.7.1.2) - Pipeline Review, H1 2016

Summary

‘Glucokinase (Hexokinase-D or Hexokinase Type IV or EC 2.7.1.2) - Pipeline Review, H1 2016’, provides in depth analysis on Glucokinase (Hexokinase-D or Hexokinase Type IV or EC 2.7.1.2) targeted pipeline therapeutics.

The report provides comprehensive information on the Glucokinase (Hexokinase-D or Hexokinase Type IV or EC 2.7.1.2), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Glucokinase (Hexokinase-D or Hexokinase Type IV or EC 2.7.1.2) targeted therapeutics development and features dormant and discontinued projects.

Our report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Glucokinase (Hexokinase-D or Hexokinase Type IV or EC 2.7.1.2)
- The report reviews Glucokinase (Hexokinase-D or Hexokinase Type IV or EC 2.7.1.2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Glucokinase (Hexokinase-D or Hexokinase Type IV or EC 2.7.1.2) targeted therapeutics and enlists all their major and minor projects
- The report assesses Glucokinase (Hexokinase-D or Hexokinase Type IV or EC 2.7.1.2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Glucokinase (Hexokinase-D or Hexokinase Type IV or EC 2.7.1.2) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Glucokinase (Hexokinase-D or Hexokinase Type IV or EC 2.7.1.2)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Glucokinase (Hexokinase-D or Hexokinase Type IV or EC 2.7.1.2) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
READ MORE
Note: Product cover images may vary from those shown
2 of 6

FEATURED COMPANIES

  • Advinus Therapeutics Ltd
  • Amgen Inc.
  • LG Life Science LTD.
  • Novartis AG
  • Poxel SA
  • Teijin Pharma Limited
  • MORE
List of Tables

List of Figures

Introduction

Report Coverage

Glucokinase (Hexokinase-D or Hexokinase Type IV or EC 2.7.1.2) Overview

Therapeutics Development

Glucokinase (Hexokinase-D or Hexokinase Type IV or EC 2.7.1.2) - Products under Development by Stage of Development

Glucokinase (Hexokinase-D or Hexokinase Type IV or EC 2.7.1.2) - Products under Development by Therapy Area

Glucokinase (Hexokinase-D or Hexokinase Type IV or EC 2.7.1.2) - Products under Development by Indication

Glucokinase (Hexokinase-D or Hexokinase Type IV or EC 2.7.1.2) - Pipeline Products Glance

Late Stage Products

Early Stage Products

Glucokinase (Hexokinase-D or Hexokinase Type IV or EC 2.7.1.2) - Products under Development by Companies

Glucokinase (Hexokinase-D or Hexokinase Type IV or EC 2.7.1.2) - Therapeutics Assessment

Assessment by Monotherapy/Combination Products

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Glucokinase (Hexokinase-D or Hexokinase Type IV or EC 2.7.1.2) - Companies Involved in Therapeutics Development

Advinus Therapeutics Ltd

Amgen Inc.

Hua Medicine (Shanghai) Ltd.

LG Life Science LTD.

Ligand Pharmaceuticals, Inc.

Novartis AG

Poxel SA

Takeda Pharmaceutical Company Limited

Teijin Pharma Limited

vTv Therapeutics Inc

Yuhan Corporation

Glucokinase (Hexokinase-D or Hexokinase Type IV or EC 2.7.1.2) - Drug Profiles

AM-9514 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GKM-001 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LC-280391 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LCZ-960 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Sinogliatin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Activate Glucokinase for Type 2 Diabetes - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Activate Glucokinase for Type 2 Diabetes - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Activate Glucokinase for Type 2 Diabetes - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TMG-123 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TTP-399 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

YH-GKA - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Glucokinase (Hexokinase-D or Hexokinase Type IV or EC 2.7.1.2) - Dormant Projects

Glucokinase (Hexokinase-D or Hexokinase Type IV or EC 2.7.1.2) - Discontinued Products

Glucokinase (Hexokinase-D or Hexokinase Type IV or EC 2.7.1.2) - Featured News & Press Releases

Apr 12, 2016: vTv Therapeutics Announces Presentation of its Diabetes Product Candidate TTP399 at the Keystone Symposia on New Therapeutics for Diabetes and Obesity

Feb 09, 2016: vTv Therapeutics Completes Enrollment of Phase 2b Trial Evaluating TTP399 for the Treatment of Type 2 Diabetes

Aug 13, 2015: Hua Medicine's GKA Diabetes Drug Demonstrates High Efficacy in 4-Week Phase 1c Trial

Jun 04, 2015: vTv Therapeutics Initiates Patient Dosing in the AGATA Study, a six Month Phase 2 Study Evaluating TTP399, a Liver-selective GlucoKinase Activator, for the Treatment of Type 2 Diabetes

Mar 10, 2015: Hua Medicine Files IND in US for its Novel GKA-based Diabetes Drug

Feb 09, 2015: Hua Medicine Announces Positive Phase 1b Results in Diabetes with 4th-Generation Glucokinase Activator, Shows Robust 24-hour Glucose Control

Mar 26, 2014: Hua Medicine tests glucokinase activator in Chinese diabetics

Mar 19, 2014: Hua Medicine's Novel Glucokinase Activator Reports Positive Phase 1a Data Demonstrating Robust Glucose Regulatory Hormone Modulation & Commences Phase 1b Trials in Diabetes Patients

Aug 14, 2013: First Liver-Selective Glucokinase Activator for Type 2 Diabetes Demonstrates Normalized HbA1c and No Hypoglycemia in Clinical Trial

Nov 29, 2012: Hua Medicine's Glucokinase Activator Passes Provincial FDA Inspections, Phase I Trial Likely To Be Launched In 2013

Nov 23, 2012: Hua Medicine Advances Diabetic Drug Towards Trial

Nov 29, 2011: Advinus's Glucokinase Activator Achieves Early POC For Diabetes

Sep 07, 2010: GKM-001 Completes Phase I Single Ascending Dose Study

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer 56List of Tables

Number of Products under Development for, H1 2016

Number of Products under Development by Therapy Area, H1 2016

Number of Products under Development by Indication, H1 2016

Comparative Analysis by Late Stage Development, H1 2016

Comparative Analysis by Early Stage Products, H1 2016

Number of Products under Development by Companies, H1 2016

Products under Development by Companies, H1 2016

Assessment by Monotherapy/Combination Products, H1 2016

Number of Products by Stage and Mechanism of Action, H1 2016

Number of Products by Stage and Route of Administration, H1 2016

Number of Products by Stage and Molecule Type, H1 2016

Pipeline by Advinus Therapeutics Ltd, H1 2016

Pipeline by Amgen Inc., H1 2016

Pipeline by Hua Medicine (Shanghai) Ltd., H1 2016

Pipeline by LG Life Science LTD., H1 2016

Pipeline by Ligand Pharmaceuticals, Inc., H1 2016

Pipeline by Novartis AG, H1 2016

Pipeline by Poxel SA, H1 2016

Pipeline by Takeda Pharmaceutical Company Limited, H1 2016

Pipeline by Teijin Pharma Limited, H1 2016

Pipeline by vTv Therapeutics Inc, H1 2016

Pipeline by Yuhan Corporation, H1 2016

Dormant Projects, H1 2016

Discontinued Products, H1 2016 44List of Figures

Number of Products under Development for, H1 2016

Comparative Analysis by Early Stage Products, H1 2016

Assessment by Monotherapy/Combination Products, H1 2016

Number of Products by Stage and Mechanism of Actions, H1 2016

Number of Products by Stage and Routes of Administration, H1 2016

Number of Products by Stage and Molecule Type, H1 2016
Note: Product cover images may vary from those shown
3 of 6

Loading
LOADING...

4 of 6

FEATURED COMPANIES

  • Advinus Therapeutics Ltd
  • Amgen Inc.
  • LG Life Science LTD.
  • Novartis AG
  • Poxel SA
  • Teijin Pharma Limited
  • MORE
According to our recently published report 'Glucokinase – Pipeline Review, H1 2016'; Glucokinase (Hexokinase-D or Hexokinase Type IV or EC 2.7.1.2) pipeline Target constitutes close to 11 molecules. Out of which approximately 11 molecules are developed by Companies.

Furthermore, the publisher says; Glucokinase (Hexokinase-D or Hexokinase Type IV or EC 2.7.1.2) Glucokinase is an enzyme that catalyzes the initial step in utilization of glucose by the beta-cell and liver at physiological glucose concentration. The role of GCK is to provide G6P for the synthesis of glycogen. Pancreatic glucokinase plays an important role in modulating insulin secretion. Hepatic glucokinase helps to facilitate the uptake and conversion of glucose by acting as an insulin-sensitive determinant of hepatic glucose usage.

The report 'Glucokinase – Pipeline Review, H1 2016' outlays comprehensive information on the Glucokinase (Hexokinase-D or Hexokinase Type IV or EC 2.7.1.2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Glucokinase (Hexokinase-D or Hexokinase Type IV or EC 2.7.1.2) targeted therapeutics development, features dormant and discontinued projects and latest news and press releases. Currently, The molecules developed by Companies in Phase II, Phase I, Preclinical and Discovery stages are 3, 1, 6 and 1 respectively.
Note: Product cover images may vary from those shown
5 of 6
Advinus Therapeutics Ltd
Amgen Inc.
Hua Medicine (Shanghai) Ltd.
LG Life Science LTD.
Ligand Pharmaceuticals, Inc.
Novartis AG
Poxel SA
Takeda Pharmaceutical Company Limited
Teijin Pharma Limited
vTv Therapeutics Inc
Yuhan Corporation
Note: Product cover images may vary from those shown
6 of 6
Note: Product cover images may vary from those shown
Adroll
adroll